Serum Antibodies to Recombinant Pneumocystis Antigens
重组肺孢子虫抗原的血清抗体
基本信息
- 批准号:7188525
- 负责人:
- 金额:$ 45.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-15 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:AIDS clinical trial groupAcquired Immunodeficiency SyndromeAcuteAdultAlveolar MacrophagesAnimal ModelAntibodiesAntibody FormationAntigensAreaBiological ProcessBlood donorCD4 Lymphocyte CountCellular ImmunityCessation of lifeChildCohort StudiesDataDiagnosisEnzyme-Linked Immunosorbent AssayEpidemiologyEpitopesGeographic LocationsGoalsHIVHighly Active Antiretroviral TherapyHost DefenseHumanHumoral ImmunitiesImmune responseImmunocompromised HostImmunologyInfectionIntegration Host FactorsInternationalLeadLengthLocalizedLocationMeasuresMembrane GlycoproteinsOrganismParentsPatientsPhagocytosisPlayPneumocystisPneumoniaPopulationPredispositionProtease InhibitorReagentRecombinantsRecoveryRecurrenceRoleSeroepidemiologic StudiesSerologicalSerumStandards of Weights and MeasuresT-Lymphocyte EpitopesTimeVariantViral Load resultWeekdefense responseextracellularmacrophageresponsetool
项目摘要
DESCRIPTION (provided by applicant): Pneumocystis (Pc) is a major cause of lethal pneumonia (P) in HIV patients, but seroepidemiological studies have been severely limited by the lack of suitable reagents. I have developed recombinant fragments (A, B,C) of the human PC major surface glycoprotein (Msg) and found that one of them, MsgC, shows considerable promise as an antigen for these studies in an enzyme linked immunosorbent assay (ELISA). I hypothesize that MsgC is a universal serologic marker for PC infection, and that the highest level of antibodies will be found in HIV patients who recovered from PcP (PcP+). The goals of this proposal are to analyze serum antibody responses, as well as the host factors that influence these responses, to the Msg fragments in adult HIV PcP+ patients, HIV patients who never had PcP (PcP-), and healthy blood donors in 8 different international locations. Data obtained from these studies will lead to the first standard antigen for PC serologic studies, and enhance our understanding of the epidemiology and immunology of PC infection.
描述(由申请人提供):肺炎(PC)是HIV患者致死性肺炎(P)的主要原因,但是由于缺乏合适的试剂,血清ePIDEMIologology研究受到严重限制。我已经开发了人类PC主要表面糖蛋白(MSG)的重组片段(A,B,C),发现其中一个是MSGC,在酶连接的免疫吸收测定法(ELISA)中,作为这些研究的抗原表现出巨大的希望。我假设MSGC是PC感染的通用血清学标记,并且在从PCP(PCP+)中恢复的HIV患者中会发现最高水平的抗体。该提案的目标是分析对这些反应的血清抗体反应以及影响这些反应的宿主因素,对成人HIV PCP+患者的MSG片段,从未患有PCP(PCP-)的HIV患者以及8个不同国际位置的健康献血者。从这些研究中获得的数据将导致PC血清学研究的首个标准抗原,并增强我们对PC感染流行病学和免疫学的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER D WALZER其他文献
PETER D WALZER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER D WALZER', 18)}}的其他基金
Serum Antibodies to Recombinant Pneumocystis Antigens
重组肺孢子虫抗原的血清抗体
- 批准号:
7585265 - 财政年份:2005
- 资助金额:
$ 45.08万 - 项目类别:
Global Serological Study of Pneumocystis Infection
肺孢子虫感染的全球血清学研究
- 批准号:
7114021 - 财政年份:2005
- 资助金额:
$ 45.08万 - 项目类别:
Global Serological Study of Pneumocystis Infection
肺孢子虫感染的全球血清学研究
- 批准号:
6934161 - 财政年份:2005
- 资助金额:
$ 45.08万 - 项目类别:
Serum Antibodies to Recombinant Pneumocystis Antigens
重组肺孢子虫抗原的血清抗体
- 批准号:
7388815 - 财政年份:2005
- 资助金额:
$ 45.08万 - 项目类别:
SP-A MOUSE MODELS OF PNEUMOCYSTIS INFECTION
肺孢子虫感染的 SP-A 小鼠模型
- 批准号:
6077013 - 财政年份:2000
- 资助金额:
$ 45.08万 - 项目类别:
SP-A MOUSE MODELS OF PNEUMOCYSTIS INFECTION
肺孢子虫感染的 SP-A 小鼠模型
- 批准号:
6638606 - 财政年份:2000
- 资助金额:
$ 45.08万 - 项目类别:
SP-A MOUSE MODELS OF PNEUMOCYSTIS INFECTION
肺孢子虫感染的 SP-A 小鼠模型
- 批准号:
6735630 - 财政年份:2000
- 资助金额:
$ 45.08万 - 项目类别:
SP-A MOUSE MODELS OF PNEUMOCYSTIS INFECTION
肺孢子虫感染的 SP-A 小鼠模型
- 批准号:
6390669 - 财政年份:2000
- 资助金额:
$ 45.08万 - 项目类别:
SP-A MOUSE MODELS OF PNEUMOCYSTIS INFECTION
肺孢子虫感染的 SP-A 小鼠模型
- 批准号:
6537755 - 财政年份:2000
- 资助金额:
$ 45.08万 - 项目类别:
PNEUMOCYSITIS CARINII INFECTION THERAPIES--PRECLIN EVAL
卡氏肺囊虫感染治疗 - PRECLIN 评估
- 批准号:
6334487 - 财政年份:1997
- 资助金额:
$ 45.08万 - 项目类别:
相似海外基金
A randomized controlled pilot study to examine the impact of a filmed dramatized story intervention (telenovela/soap opera) for HIV prevention in Latinas
一项随机对照试点研究,旨在检验电影化故事干预(电视剧/肥皂剧)对拉丁裔艾滋病毒预防的影响
- 批准号:
10673607 - 财政年份:2022
- 资助金额:
$ 45.08万 - 项目类别:
Adolescent-tailored HIV treatment and prevention strategies in South Africa: projecting clinical benefits and value
南非针对青少年的艾滋病毒治疗和预防策略:预测临床效益和价值
- 批准号:
10619497 - 财政年份:2022
- 资助金额:
$ 45.08万 - 项目类别:
A randomized controlled pilot study to examine the impact of a filmed dramatized story intervention (telenovela/soap opera) for HIV prevention in Latinas
一项随机对照试点研究,旨在检验电影化故事干预(电视剧/肥皂剧)对拉丁裔艾滋病毒预防的影响
- 批准号:
10403030 - 财政年份:2022
- 资助金额:
$ 45.08万 - 项目类别:
Adolescent-tailored HIV treatment and prevention strategies in South Africa: projecting clinical benefits and value
南非针对青少年的艾滋病毒治疗和预防策略:预测临床效益和价值
- 批准号:
10707187 - 财政年份:2022
- 资助金额:
$ 45.08万 - 项目类别:
A Comprehensive Community-based Strategy to Optimize the HIV Prevention and Treatment Continuum for Youth At HIV Risk, Acutely Infected and with Established HIV Infection
一项以社区为基础的综合战略,旨在优化处于艾滋病毒风险、急性感染和已确诊艾滋病毒感染的青少年的艾滋病毒预防和治疗连续性
- 批准号:
10397368 - 财政年份:2021
- 资助金额:
$ 45.08万 - 项目类别: